Drug Discovery App CS WP

31. Process Development Considerations For RNA-LNP Therapeutics 9/13/2022

    Here, we highlight three important process considerations across the RNA-LNP manufacturing workflow which includes limit size behavior, in-line dilution and downstream tangential flow filtration (TFF).

32. Key Stages In mRNA-Based Therapeutic Development 9/13/2022

    Learn how planning a product development strategy early on with a technology partner who has deep expertise and technical knowledge of genomic medicines can address uncertainties from the outset.

33. Expansion Of Porcine SK-RST Cells On Microcarriers Via Serial Passage In Stirred Vessels 9/7/2022

    By performing a small-scale study with multiple microcarrier types and medias we identify the best microcarrier and media for the expansion of porcine SK-RST cells via microcarrier-based serial passage in stirred vessels.

34. SPR Assays To The Assess Similarity Between Innovator And Biosimilar Versions of Nivolumab (Opdivo®) 9/2/2022

    Learn more about developed and qualified SPR assays to characterize the binding and affinity of biosimilar and innovator nivolumab for all seven Fc gamma receptors, FcRn and PD-1.

     

35. Expansion Of MRC-5 Cells On Microcarriers Via Serial Passage In Stirred Vessels 9/1/2022

    In this application note we characterize MRC-5 cell growth on multiple microcarriers in stirred vessels and present data demonstrating feasibility of serial passage and scale-up into bioreactor expansion of MRC-5 cells.

36. Microcarrier Delivery System For Reduced Bioreactor Set Up Time 9/1/2022

    This paper evaluates a gamma irradiated, ready-to-use microcarrier delivery system that reduced bioreactor set up time by approximately by 20%.

37. Expansion Of MDCK Cells On Microcarriers Via Growth In Stirred Vessels 8/31/2022

    We demonstrate how microcarriers provide an ideal substrate for expansion of MDCK cells in closed stirred-vessel systems and lay the groundwork for subsequent developmental studies in larger bioreactor formats.

38. Fast, Flexible, And Intelligent Solutions For Buffer Preparation 8/30/2022

    We explore a unique single-use technology platform fitting all mixing applications from buffer and media preparations, downstream processes to final formulation in 50 L, 100 L, 200 L, 400 L, 650 L and 1,000 L volumes.

39. Abeona Therapeutics Demonstrates Effective Scalability Of Suspension Cells For The Production Of rAAV Viral Vectors 8/30/2022

    Learn how this gene therapy company leveraged a scalable production platform to  make process development and subsequent scale-up more streamlined offering time and cost savings.

40. Move Your Gene Therapy From Strategy To Reality 8/30/2022

    Explore how optimizing your process with an end-to-end integrated solution can reduce costs, increase speed to market and get your final gene therapy product within reach of patients.